Combination of targeted therapies could help overcome treatment resistance in advanced prostate cancer
UCLA researchers have identified a promising strategy to make a new class of targeted cancer therapies more effective against one of the deadliest forms of prostate cancer, potentially overcoming treatment resistance that has limited their success.
UCLA researchers have identified a promising strategy to improve the effectiveness of antibody-drug conjugates (ADCs) in treating metastatic castration-resistant prostate cancer, a deadly form of the disease that no longer responds to hormone therapy. ADCs, which deliver potent chemotherapy directly to tumors while minimizing damage to healthy tissue, have shown limited success in prostate cancer.
The new research, published in the Journal of Clinical Investigation, suggests that combining ADCs with a drug that blocks the BCL-XL protein could make cancer cells more susceptible to treatment. In laboratory and animal models, this combination led to increased cancer cell death and slowed tumor growth, indicating a potential new approach for developing advanced prostate cancer therapies.
The study's lead author, Dr. John Lee, emphasized the framework's potential for engineering more effective ADCs by pairing complementary drug payloads and targeting multiple proteins on prostate cancer cells.
Brief written by urgent.news from Medical Xpress's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
